Fornidd: Gastrointestinal symptoms such as nausea, vomiting, diarrhoea, abdominal pain and loss of appetite (>10%) are very common: these occur most frequently during initiation of therapy and resolve spontaneously in most cases. To prevent these gastrointestinal symptoms, it is recommended that metformin be taken 2 or 3 daily doses during or after meals. A slow increase of the dose may also improve gastrointestinal tolerability.
Metallic taste (3%) is common.
Mild erythema has been reported in some hypersensitive individuals. The incidence of such effects is regarded as very rare (<0.01%).
A decrease of vitamin B12 absorption with decrease of serum levels has been observed in patients treated long-term with metformin and appears generally to be without clinical significance (<0.01%).
Lactic acidosis (0.03 cases/1000 patients-years) is very rare (see Warnings and Precautions).
Blood and lymphatic system disorders: Not known: Reduction of thyrotropin level in patients with hypothyroidism, hypomagnesemia in the context of diarrhea.
Nervous system disorder: Not known: Encephalopathy.
Skin and subcutaneous tissue disorders: Not known: Photosensitivity.
Metabolism and Nutrition disorders: Cases of peripheral neuropathy in patients with vitamin B12 deficiency have been reported in post-marketing experience (frequency not known) (see Warnings and Precautions).
Fornidd XR: Gastrointestinal disturbances: Nausea, diarrhea, gastric pain, constipation, vomiting, metallic taste in mouth.
Dermatological Effects: Rash, pruritus, urticaria, erythema and flushing.
Miscellaneous: Headache and dizziness. Impaired gastrointestinal absorption of vitamin B12 and folic acid has been associated with long-term Metformin Hydrochloride therapy.
However, if such symptoms occur, consult with the physician or pharmacist.